A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons
Stanislaw Rajmund Burzynski,
Gregory Burzynski,
Tomasz Janicki,
Samuel Beenken
Issue:
Volume 7, Issue 1, March 2022
Pages:
1-7
Received:
17 December 2021
Accepted:
19 January 2022
Published:
5 February 2022
Abstract: Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a slight male predominance. The case of this 25-year-old female is presented to detail and discuss the use of Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal) in the treatment of DIPG that persisted despite radiation therapy (RT) and temozolomide. Objectives: The patient described was treated at the Burzynski Clinic (BC), as a special exception, according to the phase II protocol, BT-09, which utilized Antineoplastons A10 and AS2-1 (ANP therapy) in the treatment of brain tumors. The delivery of ANP therapy was via a subclavian catheter and infusion pump. Tumor response to therapy was measured by sequential magnetic resonance imaging (MRI) of the brain. Overall Survival (OS) and Adverse Events (AES) were also documented. Findings: At her presentation to the BC, the patient complained of diplopia, left-sided weakness, and difficulty walking. On physical exam, she was alert and orientated. Her cranial nerves were intact. There was weakness of the left-sided extremities. Deep tendon reflexes were equal bilaterally with down-going toes bilaterally. Reports of the original brain MRIs in Argentina suggested a DIPG with extension to the medulla and cerebellum. In addition, tumor biopsy confirmed a grade 3 astrocytoma. Following radiation therapy (RT) and temozolomide in Argentina, the patient was treated at BC for persistent disease with ANP therapy. Sequential MRI imaging of the residual tumor, which was non-enhancing, showed no change in size during therapy. However, the patient did achieve resolution of her neurologic signs and symptoms and has survived more than nine years since first being seen at BC. Correspondence with the patient on September 9, 2021 indicated she was feeling fine, had a healthy child, and was enjoying life. Conclusions: We have presented here the case of an adult female with a DIPG who had resolution of signs and symptoms and survived more than nine years after ANP therapy. For patients with DIPG (or other high-grade astrocytoma), who do not qualify for/refuse RT or show persistent or progressive disease following RT and/or chemotherapy, ANP therapy is an effective therapeutic option. In collaboration with the FDA confirmatory Phase II and Phase III studies have been developed.
Abstract: Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of brain tumor–related death in children. Over the past few decades, clinical trials have shown no improvement in outcome. Most DIPGs occur in the pediatric population. Adult brainstem gliomas are rare, constitute less than 2% of adult gliomas, and show a s...
Show More
The Effects of Plasma-Activated Saline and Medium on Colorectal Cancer in Rat Models and the Human Colon Adenocarcinoma Cell Line COLO 205
Genu Takahashi,
Nanako Okuno,
Kyota Yoshino,
Takamichi Hirata,
Chihiro Kobayashi,
Akira Mori,
Masaya Watada
Issue:
Volume 7, Issue 1, March 2022
Pages:
8-13
Received:
14 December 2021
Accepted:
23 December 2021
Published:
9 February 2022
Abstract: Colorectal cancer affects a large number of people. There is an urgent need to develop novel treatments for this disease. In recent years, research on medical applications of atmospheric low temperature plasma (ALTP) has been actively conducted, and cancer treatment is one of the targets. In this study, we focused on colorectal cancer and evaluated plasma as a new treatment method. In vivo and in vitro experiments were conducted using plasma-treated saline (PTS) and plasma-treated medium (PTM) prepared by submerged bubbling treatment using ALTP. In vivo experiments using a rat model of colorectal cancer revealed that PTS administration to the colon slowed tumor progression based on endoscopic and histopathological observations. To investigate the cause of the inhibition of tumor progression, we evaluated the impact of ALTP on colon cancer cells. As a result of culturing colorectal cancer cells with PTM, cell proliferation was inhibited. Also, cell death was induced by cell swelling. qPCR revealed that PTMs induced cell death of cancer cells through signaling of tumor necrosis factor α (TNF-α), an inflammatory cytokine. Therefore, the inhibition of cancer progression by PTS in the rat model occurs by inducing cell death through the dissolution of ALTP components in the liquid.
Abstract: Colorectal cancer affects a large number of people. There is an urgent need to develop novel treatments for this disease. In recent years, research on medical applications of atmospheric low temperature plasma (ALTP) has been actively conducted, and cancer treatment is one of the targets. In this study, we focused on colorectal cancer and evaluated...
Show More
A Case Report on Idiopathic-Multi-centric Castleman’s Disease Associated POEMS- Syndrome
Amritha Radhakrishnan Nair,
Changaramkumarath Gichin,
Deepa Pramod Raj Santhi,
Moothiringode Chithrabhanu Savithri
Issue:
Volume 7, Issue 1, March 2022
Pages:
14-16
Received:
13 January 2022
Accepted:
3 February 2022
Published:
16 February 2022
Abstract: Castleman’s Disease is a rare lymphoproliferative disorder of idiopathic etio-pathogenesis and was first described by Dr Benjamin Castleman in 1954. It is a rather rare disease entity in clinical practice. However, the incidence cannot be ignored. It may affect a single lymph node (Unicentric CD) or multiple lymph nodes throughout the body (Multicentric CD). Management depends upon the type and severity of the disease and early recognition of the condition. Our case report is that of a 60-year-old female patient with underlying comorbidities including type 2 diabetes mellitus, hypothyroidism who presented with complaints of generalized weakness, weight loss, hair loss, non-resolving muco-purulent rhinorrhea, bilateral pedal edema and multiple, non-tender, firm and mobile left sided Level I and II ‘AJCC’ cervical lymphadenopathy of >2cm which was later biopsied and diagnosed to be Castleman’s disease associated POEMS syndrome. The aim of this report is to consider CD as a differential diagnosis in patients presenting with similar clinical picture and early identification and treatment may provide a better prognosis. We would also like to highlight 3 take home points: 1) The significance of histology in differentiating it from other lymph proliferative conditions. 2) LN excision of the bothersome LN can be diagnostic and may be considered therapeutic to some extend even in MCD. 3) Steroid therapy has beneficial effects to control progression of the disease.
Abstract: Castleman’s Disease is a rare lymphoproliferative disorder of idiopathic etio-pathogenesis and was first described by Dr Benjamin Castleman in 1954. It is a rather rare disease entity in clinical practice. However, the incidence cannot be ignored. It may affect a single lymph node (Unicentric CD) or multiple lymph nodes throughout the body (Multice...
Show More
